Affiliation:
1. Medicines and Health Products, Scientific Direction Physical and Chemical Health risks Sciensano Brussels Belgium
Abstract
AbstractAs cannabidiol (CBD) is not considered to be a drug and because of its potential health claims, it is an interesting compound that is often found in cosmetics. However, the safety of CBD, as well as the presence of trace amounts of other phytocannabinoids, including the psychoactive substance ∆9‐tetrahydrocannabinol (THC), is still being debated. A robust analytical technique capable of analysing cosmetic products and determining their phytocannabinoid content will be crucial in assessing the safety of these products. This systematic review aims to highlight the current analytical tools that could be used to analyse phytocannabinoids in cosmetics. The ideal method would be able to analyse high levels of CBD in combination with trace levels of THC and their acids. The method should provide good recoveries and accuracies in a variety of matrices while providing information on up‐coming phytocannabinoids such as cannabichromene (CBC), cannabigerol (CBG) and cannabinol (CBN). The systematic review approach was based on the Preferred Reporting Items for Systematic review and Meta‐Analyses method. The research focused on studies published from January 2010 to December 2022 in PubMed and Scopus. A total of 15 datasets met the inclusion and exclusion criteria and were tabulated to allow easy comparison. Although some of the reviewed methods can handle multiple matrices and provide satisfactory recoveries, this review process did not identify an ideal method. The most suitable methods either could not quantify phytocannabinoid acids or were not sensitive enough to quantify trace levels of psychoactive phytocannabinoids.
Reference32 articles.
1. Emerging challenges in the extraction, analysis and bioanalysis of cannabidiol and related compounds
2. WHO expert committee on drug dependence review of cannabis. Accessed 13/07/2023.https://www.who.int/news-room/questions-and-answers/item/who-expert-committee-on-drug-dependence-review-of-cannabis
3. Cosmetic ingredient database. Accessed 13/07/2023.https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-ingredient-database_en
4. EU Regulation 1223/2009 on Cosmetic products Official Journal of the European union 342/59 p.1–151.
5. InfoCuria Case‐Law C‐663/18 ‐ B S and C A [commercialisation du cannabidiol (CBD)]. n.d. Accessed 13/07/2023.https://curia.europa.eu/juris/liste.jsf?language=en&td=ALL&num=C-663/18